Clinical Trial

Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Phase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-25; most recent amendment 2025-11-28.
Status change: Not Yet Recruiting → Recruiting 2025-11-18
Trial Details
NCT Number NCT07204457
Lead Sponsor EyeGene Inc.
Collaborators: BMI Korea
Conditions Meningococcal Infections
Enrollment 1,123 participants
Start Date 2025-10-15
Primary Completion 2026-09 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-12-01